Exagamglogene autotemcel
| Clinical data | |
|---|---|
| Trade names | Casgevy |
| Other names | CTX001, exa-cel |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a624018 |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
| KEGG | |
Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. It was developed by Vertex Pharmaceuticals and Crispr Therapeutics.
The most common side effects include low levels of platelets and white blood cells, mouth sores, nausea, musculoskeletal pain, abdominal pain, vomiting, febrile neutropenia (fever and low white blood cell count), headache, and itching.
The treatment was approved for medical use in the United Kingdom in November 2023, in Bahrain in December 2023, in the United States in December 2023, in the European Union in February 2024, and in Canada in August 2025. Exagamglogene autotemcel is the first cell-based gene therapy treatment utilizing CRISPR/Cas9 gene editing technology to be approved by the US Food and Drug Administration.